(Q51805825)

12 April 2018

title

Stabilising normal and mis-sense variant alpha-glucosidase. (English)

1 reference

12 April 2018

2

John J Hopwood

1 reference

12 April 2018

author name string

Revecca Kakavanos

1

1 reference

12 April 2018

Debbie Lang

3

1 reference

12 April 2018

Peter J Meikle

4

1 reference

12 April 2018

Doug A Brooks

5

1 reference

12 April 2018

language of work or name

English

0 references

publication date

10 July 2006

1 reference

12 April 2018

published in

FEBS Letters

1 reference

12 April 2018

volume

580

1 reference

12 April 2018

issue

18

1 reference

12 April 2018

page(s)

4365-4370

1 reference

12 April 2018

Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Enzyme replacement and enhancement therapies for lysosomal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

The change in the ph 4 and ph 6 forms of α-glucosidase in cultured amniotic fluid cells and its implication in prenatal diagnosis of Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Human alpha-L-iduronidase. 2. Catalytic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

Twenty-two novel mutations in the lysosomal ?-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.06.096

10.1016/J.FEBSLET.2006.06.096

21 January 2018

Identifiers

DOI

1 reference

12 April 2018

1 reference

12 April 2018